DENTSPLY SIRONA (XRAY) has attracted fresh attention after a recent move in its share price, with the stock up around 6% over the past month and roughly 26% over the past 3 months.
That recent strength contrasts with a negative 1 year total return near 26% and deeper losses over the past 3 and 5 years. This puts the current share price of $12.95 and recent performance into a longer term context for investors.
See our latest analysis for DENTSPLY SIRONA.
The recent 26.22% 3 month share price return and 6.06% 1 month share price return contrast with a 25.86% 1 year total shareholder return decline. This indicates that recent momentum is building off a weaker longer term record.
If this move in DENTSPLY SIRONA has you reassessing where you look for opportunities in healthcare, it could be a good time to scan our 25 healthcare AI stocks as a fresh source of ideas.
With DENTSPLY SIRONA trading around $12.95, close to its analyst price target and with an intrinsic value estimate suggesting a large discount, the key question is whether there is a genuine opportunity here or whether the market is already pricing in future growth.
The most followed narrative places DENTSPLY SIRONA’s fair value at $12.97, almost exactly in line with the last close at $12.95. This keeps the focus on what could shift that balance.
The latest analyst price target for DENTSPLY SIRONA has been adjusted in a tight US$1 range, reflecting mixed recent revisions and updated views on growth, profitability, discount rate assumptions and future P/E expectations. The stock continues to appear in some firms' preferred ideas lists.
Analysts are incorporating expectations for slow top line progress, a shift from losses to profits, and a higher future earnings multiple. Curious how those elements fit together? The full narrative lays out the revenue path, margin rebuild, and valuation bridge that underpin this fair value estimate.
Result: Fair Value of $12.97 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh ongoing sales pressure in key categories and recent goodwill impairments, both of which raise questions about how durable the current recovery narrative really is.
Find out about the key risks to this DENTSPLY SIRONA narrative.
If this view does not line up with your own thinking, or you simply prefer to test the data yourself, you can build a customised story for DENTSPLY SIRONA in just a few minutes, starting with Do it your way.
A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
If you are serious about taking the next step with your portfolio, do not stop at one stock. Use the screeners below to spot opportunities first.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com